Considerations for Targeting Malignant Stem Cells in Leukemia

Cancer Control

Volumn 11, Issue 2, 2004, Pages 97-104

  Guzman, Monica L ^a,b   Jordan, Craig T ^a,b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOVIRUS VECTOR; BCR ABL PROTEIN; BORTEZOMIB; CALICHEAMICIN; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IMATINIB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; RETINOIC ACID; RITUXIMAB; SALICYLATE SODIUM; STAT5 PROTEIN; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; AUTOCRINE EFFECT; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DRUG TARGETING; GENE MUTATION; HUMAN; IONIZING RADIATION; LEUKEMIA; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION; REVIEW; STEM CELL; UBIQUITINATION;

EID: 2342622545     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480401100216     Document Type: Review

References (92)

1. Clarke DL, Johansson CB, Wilbertz J, et al. Generalized potential of adult neural stem cells. Science. 2000;288:1660-1663.
2. Vicario-Abejon C, Collin C, Tsoulfas P, McKay RD. Hippocampal stem cells differentiate into excitatory and inhibitory neurons. Eur J Neurosci. 2000;12:677-688.
3. McKay R. Stem cells in the central nervous system. Science. 1997;276:66-71.
4. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol. 2001;91:534-551.
5. Toma JG, Akhavan M, Fernandes KJ, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001;3:778-784.
6. Vessey CJ, de la Hall PM. Hepatic stem cells: a review. Pathology. 2001;33:130-141.
7. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell. 2000;100:157-168.
8. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988.
10. Bonnet D. Haematopoietic stem cells. J Pathol. 2002;197:430-440.
11. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol. 1995;11:35-71.
12. Fialkow PJ, Singer JW, Raskind WH, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317:468-473.
13. Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood. 1981;57:1068-1073.
14. Griffin JD, Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood. 1986;68:1185-1195.
15. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
16. Holyoake T, Jiang X, Eaves C, et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056-2064.
17. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101:3142-3149.
18. Mirro J Jr. Pathology and immunology of acute leukemia. Leukemia. 1992;6(suppl 4):13-15.
19. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
20. Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104-3112.
21. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood. 1998;92:4325-4335.
22. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol. 2000;28:660-671.
23. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood. 1996;87:4754-4761.
24. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
25. Terpstra W, Ploemacher RE, Prins A, Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood. 1996;15;88:1944-1950.
26. Guzman ML, Upchurch D, Grimes B, et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001;97:2177-2179.
27. Cohen O, Inbal B, Kissil JL, et al. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol. 1999;146:141-148.
28. Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene. 1998;17:3331-3340.
29. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature. 1995;376:596-599.
30. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347-4353.
31. Narayan G, Arias-Pulido H, Koul S, et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer. 2003;2:24.
32. Green WB, Slovak ML, Chen IM, et al. Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia. 1999;13:1960-1971.
33. Ogasawara S, Tamura G, Maesawa C, et al. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology. 1996;110:52-57.
34. Kaufmann SH, Karp JE, Svingen PA, et al: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991-1000.
35. Konopleva M, Zhao S, Hu W, et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol. 2002;118:521-534.
36. van Stijn A, van der Pol MA, Kok A, et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica. 2003;88:497-508.
37. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
38. Pyatt DW, Stillman WS, Yang Y, et al. An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood. 1999;93:3302-3308.
39. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
40. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-214.
41. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99.
42. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125-130.
43. Holyoake TL, Jiang X, Drummond MW, et al. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia. 2002;16:549-558.
44. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest. 1992;90:1232-1241.
45. Udomsakdi C, Eaves CJ, Swolin B, et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A. 1992;89:6192-6196.
46. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 1996;87:1539-1548.
47. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/ SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406-2414.
48. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res. 1998;22:1085-1096.
49. Holyoake TL, Jiang X, Jorgensen HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 2001;97:720-728.
50. Jiang X, Lopez A, Holyoake T, et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA. 1999;96:12804-12809.
51. Cobaleda C, Gutierrez-Cianca N, Perez-Lozada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lympoblastic leukemia. Blood. 2000;95:1007-1013.
52. George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lympoblastic leukemia. Blood. 2001;97:3925-3930.
53. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol leukemia Exp Ther. 2000;295:139-145
54. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
55. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
56. Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792-3800.
57. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701-4707.
58. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11:1447-1452.
59. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337.
60. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
61. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775-777.
62. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
63. Gari M, Goodeve A, Wilson G, et al. c-kit proto-oncogene exon 8 inframe deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105:894-900.
64. Abu-Duhier FM, Goodeve AC, Care RS, et al. Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol. 2003;120:464-470.
65. Traxler P. Tyrosine kinases as targets in cancer therapy: successes and failures. Expert Opin Ther Targets. 2003;7:215-234.
66. Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther. 2002;93:79-98.
67. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776.
68. Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med. 2000;192:719-728.
69. Frank DA. StAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat Res. 2003;115:267-291.
70. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003;102:1474-1479.
71. Bos JL, Verlaan-de Vries M, van der Eb AJ, et al. Mutations in N-ras predominate in acute myeloid leukemia. Blood. 1987;69:1237-1241.
72. Farr C, Gill R, Katz F, et al. Analysis of ras gene mutations in childhood myeloid leukaemia. Br J Haematol. 1991;77:323-327.
73. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyl-transferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 2000;19:6584-6593.
74. Milella M, Estrov Z, Kornblau SM, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002;99:3461-3464.
75. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-859.
76. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells. 2002;20:215-229.
77. Stadtmauer EA. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Curr Oncol Rep. 2002;4:375-380.
78. Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther. 2002;2:630-640.
79. Kordes U, Krappmann D, Heissmeyer V, et al. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14:399-402.
80. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
81. Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164:2200-2206.
82. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
83. Reuther JY, Reuther GW, Cortez D, et al. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981.
84. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55-M62.
85. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853-6866.
86. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med. 2002;8(4 suppl):S49-S54.
87. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99:16220-16225.
88. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29(suppl 1):3-9.
89. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-810.
90. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
91. Wierenga PK, Setroikromo R, Kamps G, et al. Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. Exp Hematol. 2003;31:421-427.
92. Ruiter GA, Zerp SF, Bartelink H, et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs. 2003;14:167-173.